Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D7PWY2
|
|||
| Drug Name |
GSK3965193
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Hepatitis B [ICD-11: 1E51; ICD-10: B18.1] | Phase 1 | [1] | |
| Company |
GlaxoSmithKline
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Terminal nucleotidyltransferase 4A (TENT4A) | Target Info | Inhibitor | [2] |
| Terminal nucleotidyltransferase 4B (TENT4B) | Target Info | Inhibitor | [2] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05330455) Four-part, Randomized, Double-blind (Parts 1, 2A, 3 and 4), Multi-center, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK3965193 Monotherapy in Healthy Participants and in Participants Living With Chronic Hepatitis B Infection; and GSK3965193 in Combination With Bepirovirsen in Participants Living With Chronic Hepatitis B Infection. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of GlaxoSmithKline | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.